15 research outputs found

    Neuropsychological profile of mild cognitive impairment with Lewy body disease

    Get PDF
    PhD ThesisObjective: Efforts are being made to identify dementia with Lewy bodies (DLB), the second commonest cause of neurodegenerative dementia after Alzheimer's disease (AD), in the Mild Cognitive Impairment (MCI) phase, during which intervention on the disease processes would likely be most successful. Few studies have targeted this group and the cognitive profile of MCI with Lewy bodies (MCI-LB) is therefore unclear. The present study aims to elucidate the neuropsychology of MCI-LB relative to MCI due to AD (MCI-AD) and healthy controls. Methods: In addition to age-matched controls (n = 31), participants with MCI and symptoms suggestive of LB disease were recruited from local clinics. Baseline assessment of all subjects included clinical examination, imaging (123iodinemetaiodobenzylguanidine [MIBG], dopamine transporter imaging [DaTscan]), and comprehensive neuropsychological assessments. Simple and Choice Reaction Time (SRT and CRT) and a Continuous Performance Test-AX (CPT-AX) were also administered to measure intraindividual variability (IIV) in attention using ex-Gaussian modelling of reaction times. MCI patients were diagnosed firstly following National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria for MCI. Participants with demonstrable cognitive impairment but no clinical symptoms or biomarkers for DLB were considered MCI-AD (n = 18). Within MCI-LB (n = 44), individuals with two or more consensus criteria for the diagnostic features or biomarkers of DLB (McKeith et al., 2017) were considered "Probable" MCI-LB (n = 30). White matter integrity was quantified using diffusion tensor imaging (DTI) and tract-based spatial statistics. Results: While both groups are impaired relative to controls, MCI-LB Probable performed worse than MCI-AD on processing speed (Digit Symbol Substitution Test [DSST, p = .011]), executive function (Verbal Fluency [FAS], p = .027) and visuospatial function (pareidolia task, p = .010; Visual Patterns Test, p = .019) tests. In contrast, MCI-AD scored significantly lower than MCI-LB Probable on tests of verbal learning and memory (Rey Auditory Verbal Learning Test short, p = .047, and long delay, p = .025, and retroactive interference, p = .029). DSST was the best predictor of group allocation using a stepwise discriminant analysis, F(2,76) = 36.89, p < .001, and 92.6% of MCI-LB Probable scored at or below the 16th percentile of control DSST scores. Using hierarchical linear regression, a control-informed processing speed composite fully explained group-associated variance in the visuospatial composite, RAVLT learning and RAVLT short delay recall. In contrast, FAS explained only 25.0% of group variance in the visuospatial composite and is not significantly correlated with RAVLT short delay (p = .132). MCI-LB Probable showed increased IIV using ex-Gaussian tau in CRT (p = .021, d = 1.12) and CPT-AX (p = .007, d =0.80) relative to controls, while MCI-AD differed significantly from controls in SRT tau (p = .002, d = 0.93). No difference between groups was found in white mater integrity, although the DSST showed substantial correlation with fractional anisotropy in the sample as a whole. Conclusions: The present study succeeded in demonstrating that the cognitive dysfunction typical of advanced DLB and AD is observable in the MCI phase of clinically-defined MCI-LB and MCI-AD, respectively. MCI-LB showed visuospatial, attentional and processing speed impairments. Processing speed emerged as particularly important to MCI-LB neuropsychology, suggesting a processing speed, rather than executive, mediated model of decline in MCI-LB. MCI-AD, in contrast, shows verbal learning and memory impairment. Future work should pursue this promising evidence of subtle, aetiologically-specific differences in cognition in MC

    Visuo-perceptual and decision-making contributions to visual hallucinations in mild cognitive impairment in Lewy body disease: insights from a drift diffusion analysis

    Get PDF
    Background: Visual hallucinations (VH) are a common symptom in dementia with Lewy bodies (DLB); however, their cognitive underpinnings remain unclear. Hallucinations have been related to cognitive slowing in DLB and may arise due to impaired sensory input, dysregulation in top-down influences over perception, or an imbalance between the two, resulting in false visual inferences. Methods: Here we employed a drift diffusion model yielding estimates of perceptual encoding time, decision threshold, and drift rate of evidence accumulation to (i) investigate the nature of DLB-related slowing of responses and (ii) their relationship to visuospatial performance and visual hallucinations. The EZ drift diffusion model was fitted to mean reaction time (RT), accuracy and RT variance from two-choice reaction time (CRT) tasks and data were compared between groups of mild cognitive impairment (MCI-LB) LB patients (n = 49) and healthy older adults (n = 25). Results: No difference was detected in drift rate between patients and controls, but MCI-LB patients showed slower non-decision times and boundary separation values than control participants. Furthermore, non-decision time was negatively correlated with visuospatial performance in MCI-LB, and score on visual hallucinations inventory. However, only boundary separation was related to clinical incidence of visual hallucinations. Conclusions: These results suggest that a primary impairment in perceptual encoding may contribute to the visuospatial performance, however a more cautious response strategy may be related to visual hallucinations in Lewy body disease. Interestingly, MCI-LB patients showed no impairment in information processing ability, suggesting that, when perceptual encoding was successful, patients were able to normally process information, potentially explaining the variability of hallucination incidence

    Utility of the pareidolia test in mild cognitive impairment with Lewy bodies and Alzheimer's disease

    Get PDF
    Funder: NIHR Newcastle Biomedical Research CentreFunder: Alzheimer's Research UKFunder: GE Healthcare; Id: http://dx.doi.org/10.13039/100006775Abstract: Objectives: Previous research has identified that dementia with Lewy bodies (DLB) has abnormal pareidolic responses which are associated with severity of visual hallucinations (VH), and the pareidolia test accurately classifies DLB with VH. We aimed to assess whether these findings would also be evident at the earlier stage of mild cognitive impairment (MCI) with Lewy bodies (MCI‐LB) in comparison to MCI due to AD (MCI‐AD) and cognitively healthy comparators. Methods: One‐hundred and thirty‐seven subjects were assessed prospectively in a longitudinal study with a mean follow‐up of 1.2 years (max = 3.7): 63 MCI‐LB (22% with VH) and 40 MCI‐AD according to current research diagnostic criteria, and 34 healthy comparators. The pareidolia test was administered annually as a repeated measure. Results: Probable MCI‐LB had an estimated pareidolia rate 1.2–6.7 times higher than MCI‐AD. Pareidolia rates were not associated with concurrent VH, but had a weak association with total score on the North East Visual Hallucinations Inventory. The pareidolia test was not an accurate classifier of either MCI‐LB (Area under curve (AUC) = 0.61), or VH (AUC = 0.56). There was poor sensitivity when differentiating MCI‐LB from controls (41%) or MCI‐AD (27%), though specificity was better (91% and 89%, respectively). Conclusions: Whilst pareidolic responses are specifically more frequent in MCI‐LB than MCI‐AD, sensitivity of the pareidolia test is poorer than in DLB, with fewer patients manifesting VH at the earlier MCI stage. However, the high specificity and ease of use may make it useful in specialist clinics where imaging biomarkers are not available

    Mild cognitive impairment with Lewy bodies: neuropsychiatric supportive symptoms and cognitive profile.

    Get PDF
    BACKGROUND: Recently published diagnostic criteria for mild cognitive impairment with Lewy bodies (MCI-LB) include five neuropsychiatric supportive features (non-visual hallucinations, systematised delusions, apathy, anxiety and depression). We have previously demonstrated that the presence of two or more of these symptoms differentiates MCI-LB from MCI due to Alzheimer's disease (MCI-AD) with a likelihood ratio >4. The aim of this study was to replicate the findings in an independent cohort. METHODS: Participants ⩾60 years old with MCI were recruited. Each participant had a detailed clinical, cognitive and imaging assessment including FP-CIT SPECT and cardiac MIBG. The presence of neuropsychiatric supportive symptoms was determined using the Neuropsychiatric Inventory (NPI). Participants were classified as MCI-AD, possible MCI-LB and probable MCI-LB based on current diagnostic criteria. Participants with possible MCI-LB were excluded from further analysis. RESULTS: Probable MCI-LB (n = 28) had higher NPI total and distress scores than MCI-AD (n = 30). In total, 59% of MCI-LB had two or more neuropsychiatric supportive symptoms compared with 9% of MCI-AD (likelihood ratio 6.5, p < 0.001). MCI-LB participants also had a significantly greater delayed recall and a lower Trails A:Trails B ratio than MCI-AD. CONCLUSIONS: MCI-LB is associated with significantly greater neuropsychiatric symptoms than MCI-AD. The presence of two or more neuropsychiatric supportive symptoms as defined by MCI-LB diagnostic criteria is highly specific and moderately sensitive for a diagnosis of MCI-LB. The cognitive profile of MCI-LB differs from MCI-AD, with greater executive and lesser memory impairment, but these differences are not sufficient to differentiate MCI-LB from MCI-AD
    corecore